IDYA Projected Dividend Yield
IDEAYA Biosciences Inc ( NASDAQ : IDYA )IDEAYA Biosciences is a synthetic lethality-focused precision medicine oncology company engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Co.'s primary synthetic lethality product candidate is IDE397, a clinical-stage methionine adenosyltransferase 2a inhibitor for patients with solid tumors having methylthioadenosine phosphorylase deletions. Co. is enrolling patients into a Phase 1 clinical trial designated as IDE397-001 to evaluate IDE397. Co. is targeting poly (ADP-ribose) glycohydrolase for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures. 20 YEAR PERFORMANCE RESULTS |
IDYA Dividend History Detail IDYA Dividend News IDYA Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |